Last $72.12 USD
Change Today +0.81 / 1.14%
Volume 876.5K
ENDP On Other Exchanges
As of 12:21 PM 12/19/14 All times are local (Market data is delayed by at least 15 minutes).

endo international plc (ENDP) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/4/14 - $82.16
52 Week Low
04/15/14 - $53.62
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

endo international plc (ENDP) Details

Endo International plc, a specialty healthcare company, develops, manufactures, markets, and distributes branded pharmaceutical and generic products, and medical devices worldwide. It provides branded prescription products, including Lidoderm, Opana ER, Percocet, Voltaren Gel, Frova, Supprelin LA, Vantas, Valstar, and Fortesta Gel to treat and manage pain and conditions in urology, endocrinology, and oncology. The company also offers non-branded generic products in the pain management, urology, central nervous system disorders, immunosuppression, oncology, women’s health, and hypertension markets; and pharmaceutical products in the areas of ADHD, pain, urology, and allergy. In addition, it provides various medical devices comprising AMS 700 MS series, AMS 800 artificial urinary sphincters, GreenLight XPS laser systems, Elevate anterior and posterior pelvic floor repair systems, and Monarc subfascial hammock products in the areas of men’s and women’s health, and prostate health. The company’s products also include Aveed, an injectable testosterone preparation to treat male hypogonadism; and BEMA Buprenorphine, a transmucosal form of buprenorphine in Phase III trials for treating moderate to severe chronic pain. It serves pharmacy chains directly; and hospitals, governmental agencies, pharmacies, and physicians through wholesale drug distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland.

3,371 Employees
Last Reported Date: 03/3/14
Founded in 1920

endo international plc (ENDP) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $4.3M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $157.0K
Chief Legal Officer, Executive Vice President...
Total Annual Compensation: $562.0K
Chief Operating Officer of Pharmaceuticals
Total Annual Compensation: $270.8K
Compensation as of Fiscal Year 2013.

endo international plc (ENDP) Key Developments

Trimel BioPharma SRL Announces Closing Of Exclusive Agreement for NATESTO(TM) with Endo International plc

Trimel Pharmaceuticals Corporation announced the closing of the previously communicated agreement between its subsidiary, Trimel BioPharma SRL, and an affiliate of Endo International plc, of which Endo has been granted the exclusive rights to market NATESTO(TM) in the United States and Mexico. Trimel has received an upfront payment of USD 25 million on closing of the transaction, together with a USD 5 million prepaid inventory deposit.

Endo International's Qualitest Subsidiary Announces Launch of Generic Version of Valcyte(R)

Endo International plc announced that its Qualitest subsidiary has launched a generic version of Hoffmann-La Roche Inc.'s Valcyte(R) (Valganciclovir Tablets USP, 450 mg).

Endo Receives Final Approval for Generic Version of Valcyte(R)

Endo International plc announced that its Qualitest subsidiary has received final approval from the U.S. Food and Drug Administration on its Abbreviated New Drug Application for a generic version of Hoffmann-La Roche Inc.'s Valcyte(R) (Valganciclovir Tablets USP, 450 mg).


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ENDP:US $72.12 USD +0.81

ENDP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CR Bard Inc $169.98 USD -1.60
Dr Reddy's Laboratories Ltd 3,199 INR +48.20
Hologic Inc $26.87 USD -0.085
Mallinckrodt PLC $98.90 USD +3.41
Varian Medical Systems Inc $87.44 USD +0.27
View Industry Companies

Industry Analysis


Industry Average

Valuation ENDP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.0x
Price/Book 4.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ENDO INTERNATIONAL PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at